Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxintong Capsule for Chronic Stable Angina
ChiCTR2100044563Phase 4Recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of naoxintong in angina pectoris and coronary arteriosclerosis (2 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoints: Changes in angina pectoris symptoms and Therapeutic effect on traditional Chinese medicine (TCM) syndromes. Started May 2021; status: recruiting.
02
Drugs
naoxintong
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100044563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044563.